IRVINE, Calif. - Biomerica, Inc. (NASDAQ:BMRA), a biomedical technology company, announced today that it has received an additional 180-day period from Nasdaq to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company now has until May 5, 2025, to ensure its common stock's bid price closes at or above $1.00 for at least ten consecutive business days.
The extended compliance period was granted as Biomerica meets all other listing requirements, except for the bid price. The company's written notice of its intention to cure the deficiency was also taken into consideration by Nasdaq. Biomerica is actively pursuing measures to meet the bid price requirement and is committed to maintaining its listing status.
Biomerica's portfolio includes diagnostic and therapeutic products for point-of-care and clinical laboratory use, focusing on gastrointestinal and inflammatory diseases. Among its products is the inFoods IBS test, which helps identify specific food triggers for individuals with irritable bowel syndrome (IBS) using a simple finger-stick blood sample.
The inFoods IBS test has undergone clinical studies at renowned institutions, showing significant improvement in abdominal pain for patients who followed a treatment diet compared to those on a placebo diet. These results suggest potential advantages over current IBS drugs on the market.
While the company remains optimistic about meeting future Nasdaq requirements and the efficacy of its products, it acknowledges the risks and uncertainties inherent in such forward-looking statements. These include the need for regulatory approvals, demand for products, competition, and the company's reliance on third-party manufacturers and international shipping carriers.
This news is based on a press release statement from Biomerica, Inc.
In other recent news, Biomerica Inc (NASDAQ:BMRA). has been granted an additional 180 days to meet Nasdaq's minimum bid price requirement, extending the deadline for compliance to May 2025. This follows a previous notification indicating non-compliance with Nasdaq's Listing Rule, which mandates a minimum bid price of $1.00 per share. The company is actively exploring all available options to address this deficiency.
In terms of product development, Biomerica's Fortel® Prostate (PSA) Screening Test has received approval from the Saudi Food and Drug Authority, marking a significant step in the company's strategic expansion into the Middle East. This user-friendly at-home test offers rapid detection of prostate-specific antigen, an early indicator of prostate cancer.
In addition to these developments, Biomerica has also launched a pilot program for its inFoods IBS product and secured a multi-year exclusive distribution agreement in the United Arab Emirates for its at-home cancer screening products. The company has expanded into new offices across the United States and secured five new patents for its inFoods technology in Europe, Canada, and Japan. Lastly, Biomerica announced the immediate resignation of its Board Chairman, Jack Kenny, due to personal reasons, with his successor yet to be named. These are the recent developments in the company's ongoing operations.
InvestingPro Insights
As Biomerica (NASDAQ:BMRA) works to meet Nasdaq's minimum bid price requirement, investors should consider some key financial metrics and insights from InvestingPro. The company's market capitalization stands at a modest $6.26 million, reflecting its current challenges.
One InvestingPro Tip highlights that Biomerica holds more cash than debt on its balance sheet, which could provide some financial flexibility as it navigates this critical period. This liquidity position is further supported by another tip indicating that the company's liquid assets exceed short-term obligations.
However, investors should note that Biomerica is quickly burning through cash, according to another InvestingPro Tip. This is particularly relevant given the company's need to improve its stock price performance. The company's revenue for the last twelve months was $5.51 million, with a slight growth of 1.74% over the same period.
Despite these challenges, Biomerica has shown strong returns over the last month and three months, with price total returns of 13.95% and 19.12% respectively. This recent positive momentum could be crucial as the company aims to meet the $1.00 bid price requirement.
It's worth noting that InvestingPro offers additional tips and insights that could be valuable for investors considering Biomerica's stock. In fact, there are 10 additional tips available on the InvestingPro platform, providing a more comprehensive analysis of the company's financial health and market position.
This article was enriched with data from InvestingPro. For more insights and tips on Biomerica (BMRA), check out InvestingPro's comprehensive analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.